Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Drappatz

Showing results (71-80 of 130) with videos related to

Pageof 13
Sort By:
Journal of Neuro-Oncology|September 8, 2010
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomideElizabeth R Gerstner, April F Eichler, Scott R Plotkin, et al.
Frontiers in Oncology|May 24, 2021
Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 PandemicNa Tosha N Gatson, Jill Barnholtz-Sloan, Jan Drappatz, et al.
Neuro-Oncology Advances|May 4, 2026
Clinical characteristics and outcomes of adult IDH-mutant brainstem gliomas: Institutional case series and systematic reviewMaged T Ghoche, Kenji Miki, Fanen Yuan, et al.
Neuro-Oncology|October 17, 2017
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapyTimothy F Cloughesy, Jan Drappatz, John de Groot, et al.
Neuro-Oncology|October 11, 2017
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapyPatrick Y Wen, Jan Drappatz, John de Groot, et al.
The Oncologist|June 11, 2020
Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical TrialJorg Dietrich, Laura Versmee, Jan Drappatz, et al.
Neuro-Oncology|December 19, 2015
Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumorsMarina N Nikiforova, Abigail I Wald, Melissa A Melan, et al.
Journal of Neuro-Oncology|December 16, 2014
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort studyMilan G Chheda, Patrick Y Wen, Fred H Hochberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 14, 2011
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphomaGregory M Cote, Ephraim P Hochberg, Alona Muzikansky, et al.
Neuro-Oncology Advances|December 23, 2024
Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade gliomaCrismita Dmello, Andrew Brenner, David Piccioni, et al.
Pageof 13

Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
Journal of Neuro-Oncology|September 8, 2010
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomideElizabeth R Gerstner, April F Eichler, Scott R Plotkin, et al.
Frontiers in Oncology|May 24, 2021
Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 PandemicNa Tosha N Gatson, Jill Barnholtz-Sloan, Jan Drappatz, et al.
Neuro-Oncology Advances|May 4, 2026
Clinical characteristics and outcomes of adult IDH-mutant brainstem gliomas: Institutional case series and systematic reviewMaged T Ghoche, Kenji Miki, Fanen Yuan, et al.
Neuro-Oncology|October 17, 2017
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapyTimothy F Cloughesy, Jan Drappatz, John de Groot, et al.
Neuro-Oncology|October 11, 2017
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapyPatrick Y Wen, Jan Drappatz, John de Groot, et al.
The Oncologist|June 11, 2020
Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical TrialJorg Dietrich, Laura Versmee, Jan Drappatz, et al.
Neuro-Oncology|December 19, 2015
Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumorsMarina N Nikiforova, Abigail I Wald, Melissa A Melan, et al.
Journal of Neuro-Oncology|December 16, 2014
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort studyMilan G Chheda, Patrick Y Wen, Fred H Hochberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 14, 2011
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphomaGregory M Cote, Ephraim P Hochberg, Alona Muzikansky, et al.
Neuro-Oncology Advances|December 23, 2024
Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade gliomaCrismita Dmello, Andrew Brenner, David Piccioni, et al.
Pageof 13